US approval for Boehringer/Lilly's diabetes combo
This article was originally published in Scrip
Executive Summary
The US FDA has granted marketing authorisation to Boehringer Ingelheim and Lilly's Jentadueto, a single table that combines the DDP-4 inhibitor linagliptin (Tradjenta) and metformin, for the treatment of adults with type 2 diabetes.